GSK 3036656

Drug Profile

GSK 3036656

Alternative Names: GSK 3036656

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action Leucyl-tRNA synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Tuberculosis

Most Recent Events

  • 04 Aug 2017 GlaxoSmithKline completes a phase I trial in Healthy volunteers in the United Kingdom (NCT03075410)
  • 02 Apr 2017 Phase-I clinical trials in Tuberculosis (In volunteers) in United Kingdom (PO) (NCT03075410)
  • 16 Mar 2017 GlaxoSmithKline plans a phase I trial for Tuberculosis (In volunteers) in United Kingdom (NCT03075410)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top